BioNTech shares surged 13% after Summit Therapeutics reported positive data on ivonescimab. Find out why BNTX stock is a Buy.

The BioNTech SE ADR BNTX slid 1.35% to $99.27 Wednesday, on what proved to be an all-around favorable trading session for the ...

GSK’s attempt to develop the first vaccine for herpes simplex virus (HSV) has ended in failure, leaving the race open for the ...

BioNTech SE ADR closed $19.25 below its 52-week high ($119.78), which the company achieved on September 11th.

GSK Plc (NYSE:GSK) shelved on Wednesday its herpes simplex virus (HSV) vaccine development program. The recombinant protein ...

The recommendation comes just a day after the Food and Drug administration signed off on the updated vaccines from Pfizer-BioNTech and Moderna. The director of the Centers for Disease Control and ...

Analyst John Newman of Canaccord Genuity maintained a Buy rating on BioNTech SE (BNTX – Research Report), retaining the price target of ...

The newest, updated Covid-19 vaccines are now FDA-approved and available, including the mRNA ones from Pfizer-BioNTech and ...

J.P. Morgan analyst Jessica Fye maintained a Sell rating on BioNTech SE (BNTX – Research Report) today and set a price target of $91.00.

Treatment with BNT111 + cemiplimab showed a statistically significant overall response in patients with inoperable or ...

Pandemic-era mRNA technology pioneers, BioNTech and Moderna, are now focusing on developing personalised cancer vaccines.

Tempus AI, Inc. (NASDAQ: TEM, "Tempus"), a technology company leading the adoption of AI to advance precision medicine and ...